Literature DB >> 33296161

Amide-Linked C4″-Saccharide Modification of KRN7000 Provides Potent Stimulation of Human Invariant NKT Cells and Anti-Tumor Immunity in a Humanized Mouse Model.

Noemi Alejandra Saavedra-Avila, Santosh Keshipeddy1, Matthew J Guberman-Pfeffer1, Ayax Pérez-Gallegos, Neeraj K Saini, Carolina Schäfer2, Leandro J Carreño2, José A Gascón1, Steven A Porcelli, Amy R Howell1.   

Abstract

Activation of invariant natural killer T (iNKT) cells by α-galactosylceramides (α-GalCers) stimulates strong immune responses and potent anti-tumor immunity. Numerous modifications of the glycolipid structure have been assessed to derive activating ligands for these T cells with altered and potentially advantageous properties in the induction of immune responses. Here, we synthesized variants of the prototypical α-GalCer, KRN7000, with amide-linked phenyl alkane substitutions on the C4″-position of the galactose ring. We show that these variants have weak iNKT cell stimulating activity in mouse models but substantially greater activity for human iNKT cells. The most active of the C4″-amides in our study showed strong anti-tumor effects in a partially humanized mouse model for iNKT cell responses. In silico analysis suggested that the tether length and degree of flexibility of the amide substituent affected the recognition by iNKT cell antigen receptors of the C4″-amide substituted glycolipids in complex with their antigen presenting molecule CD1d. Our findings establish the use of stable C4″-amide linked additions to the sugar moiety for further exploration of the immunological effects of structural modifications of iNKT cell activating glycolipids and highlight the critical need for more accurate animal models to assess these compounds for immunotherapeutic potential in humans.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33296161      PMCID: PMC8323612          DOI: 10.1021/acschembio.0c00707

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  38 in total

1.  Synthesis of 6"-triazole-substituted α-GalCer analogues as potent iNKT cell stimulating ligands.

Authors:  Nora Pauwels; Sandrine Aspeslagh; Dirk Elewaut; Serge Van Calenbergh
Journal:  Bioorg Med Chem       Date:  2012-10-12       Impact factor: 3.641

Review 2.  Switching invariant natural killer T (iNKT) cell response from anticancerous to anti-inflammatory effect: molecular bases.

Authors:  Xavier Laurent; Benjamin Bertin; Nicolas Renault; Amaury Farce; Silvia Speca; Ophélie Milhomme; Régis Millet; Pierre Desreumaux; Eric Hénon; Philippe Chavatte
Journal:  J Med Chem       Date:  2014-02-12       Impact factor: 7.446

Review 3.  Unconventional T Cell Targets for Cancer Immunotherapy.

Authors:  Dale I Godfrey; Jérôme Le Nours; Daniel M Andrews; Adam P Uldrich; Jamie Rossjohn
Journal:  Immunity       Date:  2018-03-20       Impact factor: 31.745

4.  Human CD1d knock-in mouse model demonstrates potent antitumor potential of human CD1d-restricted invariant natural killer T cells.

Authors:  Xiangshu Wen; Ping Rao; Leandro J Carreño; Seil Kim; Agnieszka Lawrenczyk; Steven A Porcelli; Peter Cresswell; Weiming Yuan
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-04       Impact factor: 11.205

5.  The roles of 3' and 4' hydroxy groups in alpha-galactosylceramide stimulation of invariant natural killer T cells.

Authors:  Chengfeng Xia; Wenpeng Zhang; Yalong Zhang; Wenlan Chen; Janos Nadas; Ryan Severin; Robert Woodward; Bin Wang; Xin Wang; Mitchell Kronenberg; Peng G Wang
Journal:  ChemMedChem       Date:  2009-11       Impact factor: 3.466

6.  Tissue-Specific Distribution of iNKT Cells Impacts Their Cytokine Response.

Authors:  You Jeong Lee; Haiguang Wang; Gabriel J Starrett; Vanessa Phuong; Stephen C Jameson; Kristin A Hogquist
Journal:  Immunity       Date:  2015-09-08       Impact factor: 31.745

7.  CD1d-lipid-antigen recognition by the semi-invariant NKT T-cell receptor.

Authors:  Natalie A Borg; Kwok S Wun; Lars Kjer-Nielsen; Matthew C J Wilce; Daniel G Pellicci; Ruide Koh; Gurdyal S Besra; Mandvi Bharadwaj; Dale I Godfrey; James McCluskey; Jamie Rossjohn
Journal:  Nature       Date:  2007-06-20       Impact factor: 49.962

8.  New CD1d agonists: synthesis and biological activity of 6″-triazole-substituted α-galactosyl ceramides.

Authors:  Peter J Jervis; Lisa M Graham; Erin L Foster; Liam R Cox; Steven A Porcelli; Gurdyal S Besra
Journal:  Bioorg Med Chem Lett       Date:  2012-05-09       Impact factor: 2.823

9.  A rapid fluorescence-based assay for classification of iNKT cell activating glycolipids.

Authors:  Pooja Arora; Manjunatha M Venkataswamy; Andres Baena; Gabriel Bricard; Qian Li; Natacha Veerapen; Rachel Ndonye; Jeong Ju Park; Ji Hyung Lee; Kyung-Chang Seo; Amy R Howell; Young-Tae Chang; Petr A Illarionov; Gurdyal S Besra; Sung-Kee Chung; Steven A Porcelli
Journal:  J Am Chem Soc       Date:  2011-03-22       Impact factor: 15.419

10.  Kinetics and cellular site of glycolipid loading control the outcome of natural killer T cell activation.

Authors:  Jin S Im; Pooja Arora; Gabriel Bricard; Alberto Molano; Manjunatha M Venkataswamy; Ian Baine; Elliot S Jerud; Michael F Goldberg; Andres Baena; Karl O A Yu; Rachel M Ndonye; Amy R Howell; Weiming Yuan; Peter Cresswell; Young-Tae Chang; Petr A Illarionov; Gurdyal S Besra; Steven A Porcelli
Journal:  Immunity       Date:  2009-06-19       Impact factor: 31.745

View more
  1 in total

1.  A humanized mouse model for in vivo evaluation of invariant Natural Killer T cell responses.

Authors:  Noemi Alejandra Saavedra-Avila; Paolo Dellabona; Giulia Casorati; Natacha Veerapen; Gurdyal S Besra; Amy R Howell; Steven A Porcelli
Journal:  Front Immunol       Date:  2022-10-03       Impact factor: 8.786

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.